Needham & Company initiates coverage on Aeglea Biotherapeutics (NASDAQ: AGLE) with a Buy rating and a price target of $18.00.Analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE